Oct 26, 2016 1 min read

CANONSBURG — Mylan N.V. on Wednesday announced the U.S. launches of the first generic versions of Daiichi Sankyo’s Benicar and Benicar HCT, olmesartan medoxomil tablets in 5-, 20- and 40-mg doses, and olmesartan medoxomil and hydrochlorothiazide tablets, 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg, respectively.

Mylan, whose operational headquarters are based in Southpointe, said in a news release it received final approval from the U.S. Food and Drug Administration for its abbreviated new drug applications for these products.

The tablets are indicated for the treatment of hypertension, along or with other antihypertensive agents, to lower blood pressure. olmesartan medoxomil and hydrochlorothiazide tablets are indicted for the treatment of hypertension to lower blood pressure.

The tablets had U.S. sales of approximately $1 billion for the 12 months ending Aug. 31, according to IMS Health. The olmesartan medoxomil and hydrochlorothiazide tablets had U.S. sales of approximately $805 million during that same